- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
NanoBio(R) Corporation, a biopharmaceutical company focused on developing and commercializing novel products for the prevention and treatment of infectious diseases, today announced the appointment of David M. Stout to its Board of Directors. Mr. Stout most recently served as President of Pharmaceutical Operations for GlaxoSmithKline Pharmaceuticals.
"We are pleased to welcome David to our Board of Directors and look forward to benefiting from his guidance and contributions," said James R. Baker Jr., M.D., chairman of NanoBio Corporation. "David's 30-plus years of experience in all facets of the pharmaceutical industry -- including his recent experience as head of global pharmaceutical operations for GSK, a world leader in infectious diseases -- will be invaluable to NanoBio as we approach the commercialization of our lead anti-infective and vaccine product candidates."
NanoBio's lead products are topical lotions and mucosal vaccines to combat a wide array of viruses, bacteria and fungi. They include topical treatments for herpes labialis (cold sores), onychomycosis (nail fungus) and bacterial skin infections (including MRSA), as well as mucosal vaccines for seasonal and pandemic influenza, hepatitis B and RSV. The company's nanoemulsion-based products have demonstrated potent antimicrobial effects in several clinical trials, without safety concerns or systemic absorption. The products use a physical mode of action rather than chemical synthesis to disrupt pathogen membranes, rendering the emergence of drug resistance unlikely.
"The platform technology upon which NanoBio's products are based represents a truly novel approach to combating infections and provides a rich pipeline of anti-infective products and vaccines for the future," Stout said. "Given the company's recent and very compelling clinical results, I am particularly excited to be joining the company's board at this time. I look forward to working with NanoBio's management in bringing these new therapies and vaccines to the market."
In his most recent position as President of Pharmaceutical Operations at GSK, Mr. Stout led all global commercial activities, global manufacturing and all vaccine-related activities, including research and development, as well as other executive functions. Additionally, Mr. Stout directed the corporate pandemic flu preparedness program, an international effort that supports governments, health authorities and company employees around the world in planning to respond to a global influenza pandemic. Prior to his tenure at GSK, Mr. Stout held executive leadership positions at Glaxo Wellcome, SmithKline Beecham and Schering-Plough Corporation.
About NanoBio(R) Corporation
NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus) and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.
For more information, please click here
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Chemical trickery corrals 'hyperactive' metal-oxide cluster December 8th, 2016